
Companion Diagnostics Market by Technology (Immunohistochemistry, In Situ Hybridization, Next-Generation Sequencing), Indication (Breast Cancer, Colorectal Cancer, Leukemia), End-User - Global Forecast 2024-2030
Description
Companion Diagnostics Market by Technology (Immunohistochemistry, In Situ Hybridization, Next-Generation Sequencing), Indication (Breast Cancer, Colorectal Cancer, Leukemia), End-User - Global Forecast 2024-2030
The Companion Diagnostics Market size was estimated at USD 2.62 billion in 2023 and expected to reach USD 2.92 billion in 2024, at a CAGR 11.55% to reach USD 5.63 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Companion Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Companion Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Companion Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abnova Corporation, Agilent Technologies, Inc., Almac Group, Amoy Diagnostics Co., Ltd., Archerdx, Inc., ARUP Laboratories, Biogenex Laboratories, Inc, bioMérieux SA, Danaher Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Foundation Medicine, Inc., Guardant Health, Inc, Illumina, Inc., Invivoscribe Technologies, Inc., Myriad Genetics, Inc., NG biotech, R-Biopharm AG, Sysmex Corporation, and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage
This research report categorizes the Companion Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:
Technology
Immunohistochemistry
In Situ Hybridization
Next-Generation Sequencing
Polymerase Chain Reaction
Indication
Breast Cancer
Colorectal Cancer
Leukemia
Lung Cancer
Melanoma
End-User
Biopharmaceutical Companies
Pharmaceutical
Reference Laboratories
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Companion Diagnostics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Companion Diagnostics Market?
3. What are the technology trends and regulatory frameworks in the Companion Diagnostics Market?
4. What is the market share of the leading vendors in the Companion Diagnostics Market?
5. Which modes and strategic moves are suitable for entering the Companion Diagnostics Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
197 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Companion Diagnostics Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing significance of companion diagnostics in drug development
- 5.1.1.2. Increasing demand for personalized medicines and targeted therapy
- 5.1.1.3. Rise in R&D for development of next generation sequencing
- 5.1.2. Restraints
- 5.1.2.1. High costs of companion diagnostics
- 5.1.3. Opportunities
- 5.1.3.1. Technological advancements in diagnostic techniques
- 5.1.3.2. Growing approval rate for companion diagnostics
- 5.1.4. Challenges
- 5.1.4.1. Reimbursement issues associated with companion diagnostic tests
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Companion Diagnostics Market, by Technology
- 6.1. Introduction
- 6.2. Immunohistochemistry
- 6.3. In Situ Hybridization
- 6.4. Next-Generation Sequencing
- 6.5. Polymerase Chain Reaction
- 7. Companion Diagnostics Market, by Indication
- 7.1. Introduction
- 7.2. Breast Cancer
- 7.3. Colorectal Cancer
- 7.4. Leukemia
- 7.5. Lung Cancer
- 7.6. Melanoma
- 8. Companion Diagnostics Market, by End-User
- 8.1. Introduction
- 8.2. Biopharmaceutical Companies
- 8.3. Pharmaceutical
- 8.4. Reference Laboratories
- 9. Americas Companion Diagnostics Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Companion Diagnostics Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Companion Diagnostics Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. Abbott Laboratories
- 13.1.2. Abnova Corporation
- 13.1.3. Agilent Technologies, Inc.
- 13.1.4. Almac Group
- 13.1.5. Amoy Diagnostics Co., Ltd.
- 13.1.6. Archerdx, Inc.
- 13.1.7. ARUP Laboratories
- 13.1.8. Biogenex Laboratories, Inc
- 13.1.9. bioMérieux SA
- 13.1.10. Danaher Corporation
- 13.1.11. Eli Lilly and Company
- 13.1.12. F. Hoffmann-La Roche AG
- 13.1.13. Foundation Medicine, Inc.
- 13.1.14. Guardant Health, Inc
- 13.1.15. Illumina, Inc.
- 13.1.16. Invivoscribe Technologies, Inc.
- 13.1.17. Myriad Genetics, Inc.
- 13.1.18. NG biotech
- 13.1.19. R-Biopharm AG
- 13.1.20. Sysmex Corporation
- 13.1.21. Thermo Fisher Scientific Inc.
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. COMPANION DIAGNOSTICS MARKET RESEARCH PROCESS
- FIGURE 2. COMPANION DIAGNOSTICS MARKET SIZE, 2023 VS 2030
- FIGURE 3. COMPANION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. COMPANION DIAGNOSTICS MARKET DYNAMICS
- FIGURE 7. COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
- FIGURE 8. COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
- FIGURE 10. COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 12. COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. COMPANION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. COMPANION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.